Discovery Pipeline

Sep 14, 2018
By BioPharm International Editors
Researchers from Ruhr-Universität Bochum in Germany and the National Institutes of Health modified the protein Nurr1 to enter cells from the outside, possibly enabling the protein to become a drug development candidate for illnesses such as Parkinson’s disease.
Sep 14, 2018
By BioPharm International Editors
Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies (mAbs) that can neutralize norovirus, a virus that causes acute gastrointestinal (GI) illness.
Apr 09, 2018
By BioPharm International Editors
National Institutes of Health researchers use genomics to show that squamous cell carcinomas differ from other cancers, which could advance treatments for head and neck and other cancers.
Mar 06, 2018
By BioPharm International Editors
The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.
Jan 11, 2018
By BioPharm International Editors
A Takeda and Denali collaboration includes three named programs for treating Alzheimer’s disease and other neurodegenerative diseases, using Denali’s antibody transport vehicle (ATV) technology to enhance blood-brain barrier penetration.
Jan 05, 2018
By BioPharm International Editors
The companies aim to develop a potential zinc finger protein transcription factor-based gene therapy for treating Lou Gehrig’s disease.
Jan 05, 2018
By BioPharm International Editors
The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.
Aug 23, 2017
By BioPharm International Editors
AstraZeneca and Champions will develop new cohorts of patient-derived xenograft models to be used in oncology programs in breast and lung cancer as well as for use in other academic and industry applications.
May 08, 2017
Biomedical researcher shares insights from a career dedicated to advancing therapeutic innovations for unmet medical needs.
Mar 28, 2017
By BioPharm International Editors
The company has signed two separate agreements with the Agency for Science, Technology, and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
native1_300x100
lorem ipsum